Covaxin, India’s first home-made shots against COVID-19, has shown a high degree of antibody response in mid-tier testing. “Covishield novel is highly effective vaccine against coronavirus,” said Adar Poonawalla
The second phase of COVID-19 vaccination in India started from this month. The central government had earlier approved the emergency use of Covishield by Seram Institute of India and Covaxin by Bharat Biotech. In India, beneficiaries receive two doses of the vaccine at an interval of 28 days.
Covaxin, India’s first home-made shots against COVID-19, has shown a high degree of antibody response in a mid-stage trial. The company stated that it had shown 81% efficacy in preventing symptomatic COVID-19 based on an interim analysis of late-stage trials.
The vaccine has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), Pune. Covaxin is an inactivated vaccine that is chemically treated with novel coronavirus samples to make it incapable of reproduction.
The researchers stated that the two-stage vaccine significantly neutralized the antibody responses in the second phase compared to the first phase, which was 4-weeks apart from the 2-week course of the injection schedule. Researchers said in the study published in the medical journal Lancet.
But it said that the Phase II trial, which had 380 participants, enrolled a small number of participants between 12 and 18 years of age and 55–65 years of age and conducted follow-up studies to establish immunogenetic in children and older people. Needed.
It also stated that while the trial included participants from nine Indian states, the study population lacked ethnic and gender diversity, “underscoring the importance of evaluation of BBV 152 (vaccine) in other populations”.
The local version of the Oxford-AstraZeneca COVID-19 vaccine will be known as Covishield. The Serum Institute of India, the world’s largest vaccine manufacturer, has joined hands with the British-Swedish pharmaceutical manufacturer to produce 1 billion doses of its COVID-19 vaccine.
It uses a weaker version of a chimpanzee common coldvirus that instructs to produce proteins from novel coronaviruses to generate an immune response and prevent infection.
Two doses of the vaccine, four weeks apart, were originally thought to provide the best protection against COVID-19. Scientists revealed that the overall efficacy of the Oxford vaccine was 70%, but that it could be about 90% effective when administered half a dose after a full dose a month later.
According to preliminary research, the vaccine appeared to be more than 80 percent effective at preventing serious illness in elderly, at-risk individuals after a single dose.
“The Covishield novel is a highly effective vaccine against coronovirus,” noted Adar Poonawala, CEO of the Serum Institute of India.